ANGPTL3 and familial hypercholesterolemia: In addition, the FDA recently approved evinacumab (trade name Evkeeza), a monoclonal antibody against human ANGPTL3, following phase III clinical trial results demonstrating impressive (49%) reduction in circulating LDL in patients with severe, inherited forms of hypercholesterolemia (72, 73).